Medicare GLP-1 coverage in 2026: the $50 Bridge program explained
For the first time in 20+ years, Medicare covers weight-loss drugs. What the July 2026 Bridge program covers, who qualifies, and the catches that matter.
Released: Last reviewed:
Medicare's historic shift on weight-loss drugs
For more than two decades, federal law barred Medicare from covering medications taken solely for weight loss — a ban dating to the 2003 law that created Part D. That changed on July 1, 2026, when the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge, a temporary pilot that lets eligible Part D enrollees get certain weight-loss GLP-1s for a flat $50 monthly copay. It's a significant development given that more than a third of Medicare beneficiaries have obesity, and many had faced cash prices exceeding $1,000 per month.
What the Bridge covers — and what it doesn't
The program covers specific FDA-approved weight-loss formulations: Wegovy (both the injection and the new pill), Zepbound KwikPen, and Foundayo. It does not cover single-dose Zepbound vials or pens, and it does not cover compounded GLP-1s. A standout feature is the flat copay: the $50 stays the same whether you're on a low starting dose or a high maintenance dose, which is unusual and valuable because most people need higher doses over time.
Who qualifies
Eligibility centers on being actively enrolled in a Part D plan or a Medicare Advantage plan with drug coverage, being 18 or older, meeting the clinical criteria (a qualifying BMI at the time GLP-1 therapy started), and completing a prior authorization in which your prescriber certifies you're using the drug alongside a diet-and-exercise program. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge (their Part D plan might cover a GLP-1), and neither is anyone whose Part D plan already covers their GLP-1; a prior heart attack or stroke qualifies at a BMI of 27 or more.
| Feature | Medicare GLP-1 Bridge |
|---|---|
| Start / end | July 1, 2026 – December 31, 2027 |
| Copay | $50/month flat (all doses) |
| Covered drugs | Wegovy (pill + injection), Zepbound KwikPen, Foundayo |
| Requires | Part D enrollment, prior authorization, clinical criteria |
| Counts toward Part D cap? | No |
The catches worth knowing
Three caveats matter. First, the $50 copay does not count toward the Part D annual out-of-pocket cap ($2,100 in 2026), because the Bridge runs alongside Part D rather than through it. Second, it's temporary: it runs through December 31, 2027. CMS's BALANCE page has an FAQ on "the BALANCE Model not launching in Medicare in 2027", and no specific Part D plan is required to use the Bridge. Third, it excludes compounded GLP-1s entirely, so if you're on a compounded program you'd need to switch to a covered brand product to use the benefit.
Bridge vs cash-pay compounded: which is cheaper?
For an eligible Medicare beneficiary, $50/month for an FDA-approved brand drug is hard to beat — it undercuts even the cheapest transparent cash-pay compounded programs and gives you the approved product. If you're eligible, the Bridge is very likely your lowest-cost, highest-assurance path, and worth pursuing first. If you're not eligible — because you're under 65 and not on Medicare, or you already have a Part D coverage path, or you don't meet the clinical criteria — then cash-pay options remain relevant, and a transparent flat-rate program is the predictable choice. Check eligibility with your provider before assuming either way; the paperwork is quick and the savings are large.
Frequently asked questions
Does Medicare cover weight-loss drugs in 2026?
Yes, for the first time. Starting July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy (pill and injection), Zepbound KwikPen, and Foundayo at a flat $50/month copay for eligible Part D enrollees, after a 20-plus-year federal ban on covering drugs solely for weight loss.
How much do GLP-1 drugs cost on Medicare now?
Eligible beneficiaries pay a flat $50/month copay through the GLP-1 Bridge, the same at any dose. Without the program, brand cash prices typically range from about $149 to $699/month depending on drug and dose.
Who is eligible for the Medicare GLP-1 Bridge?
Adults 18+ actively enrolled in a Part D plan or Medicare Advantage with drug coverage, who meet the clinical BMI criteria and complete a prior authorization. People already getting a GLP-1 through Part D (for diabetes, cardiovascular disease, or sleep apnea) generally aren't eligible for the Bridge.
Does the Medicare GLP-1 Bridge cover compounded semaglutide?
No. The Bridge covers only specific FDA-approved brand formulations (Wegovy, Zepbound KwikPen, Foundayo). Compounded GLP-1s are not covered.
When does the Medicare GLP-1 Bridge end?
It's scheduled to run from July 1, 2026 through December 31, 2027, and CMS's BALANCE page has an FAQ on "the BALANCE Model not launching in Medicare in 2027"; no specific Part D plan is required to use the Bridge.
References
- CMS / Medicare.gov. Weight loss drugs coverage — Medicare GLP-1 Bridge, 2026.
- Humana. Does Medicare cover GLP-1 weight loss drugs, 2026.
- NPR. Medicare launches weight-loss drug option with $50 copay, May 2026.
- CNN. Medicare to start covering weight-loss drugs July 1, June 2026.
Clinical and regulatory figures from published trials, FDA, and CMS communications; pricing from provider-advertised and manufacturer rates checked July 2026 and subject to change. Educational, not medical or financial advice.